Silence Therapeutics - Company Update
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
Strengthened Leadership, Board Appointment and Strong R&D and Corporate Progress
Strengthened leadership and Board
Silence is also pleased to announce today that Dr.
R&D progressing on track
Under Giles' R&D leadership, Silence remains on track to submit an IND package for its prioritised asset, SLN360, later this year. SLN360 continues to show great promise in being able to address increased cardiovascular risk associated with raised levels of lipoprotein (a), which is considered to affect up to 10% of the population. For its SLN124 asset, the Company has received from the FDA rare paediatric disease designation for beta-thalassaemia and orphan drug designation for myelodysplastic syndrome. Notwithstanding the constraints imposed by the COVID-19 pandemic, clinical trials with both SLN360 and SLN124 are still planned to start this year.
Corporate and business development progress
With a view to increasing coverage and expanding the Company's investor base, and as announced separately today, Investec has been appointed as Nominated Adviser (NOMAD) &
In addition, the Company has separately today announced its intention to submit a registration statement to the
Following the recent announcement of the multi-target AstraZeneca collaboration in March, the Company continues to hold discussions with a number of third parties regarding possible partnership and collaboration opportunities. Accordingly, the Company is strengthening its Business and Alliance Management capability under the leadership of
Commenting on the announcement Iain Ross, Executive Chairman, said: "Since I returned to Silence last year, the Company has advanced its innovative product pipeline, secured three validating big pharma partnerships, significantly strengthened its cash position and built a strong and experienced management team, which has proven it can execute a plan. The Company is at a critical stage of its development and I am very excited to be at the helm at this important time.
"R&D lies at the heart of Silence and Giles' experience has become increasingly paramount to the Company. I welcome him to our Board and know his input will be invaluable. As a Company we continue to monitor the potential impact of the COVID-19 pandemic on our business as we initiate clinical trials with our lead programmes and continue to further build out our capabilities and competences whilst capitalising on the immediate international interest in our Company and its proprietary RNAi programmes and platform."
Commenting on his Executive Board Appointment, Dr.
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
It has come to the Board's attention that at the time of the appointment of
Full name and age:
Current Directorships or Partnerships:
Savoy Consulting Services
Previous Directorships or Partnerships in the last 5 years:
Future Screen Partners No.1 LLP
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
For more information, please contact:
| || |
Tel: +44 (0)20 3457 6900
Investec (Nominated Adviser and Broker)
Tel: +44 (0) 20 7597 5970
Tel: +44 (0) 20 3709 5700
Tel: +1 (443) 213-0505
Giles, an expert in translational medicine, is a highly experienced biotech and pharmaceutical professional, and brings more than 30 years of experience in the industry to Silence. Most notably he served as Chief Medical Officer and Senior Vice President of R&D at Prosensa from 2009 to 2016, a European biotech company advancing oligonucleotide therapies for rare diseases, notably Duchenne muscular dystrophy (DMD). During this time the company signed a collaboration agreement with GSK worth up to
Previously, Giles held senior R&D roles at Novartis including Therapeutic Area Head Cardiovascular and Metabolic Disease and where he was a key member of a task force that defined the shape of a new integrated research and development organisation. Most recently, he served as Chief Medical Officer for Albumedix, Advisor to
Forward Looking Statements
Certain statements made in this announcement are forward-looking statements including with respect to the Company's intention to submit a registration statement to the
This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
 Varvel et al Arterioscler Thromb Vasc Biol. 2016;36:2239
This information is provided by RNS, the news service of the
Quick facts: Silence Therapeutics PLC
Market Cap: £351.18 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE